Risk and Mitigation Actions for Clinical Trials During COVID-19 Pandemic (RiMiCOPa)

Uncategorized
Category:
Published on:
January 10, 2021

COVID-19 continues to affect clinical trials, both directly and indirectly, across the world.  Each step, from protocol design to results disclosure, needs to be revised to assess COVID-19 impact, evaluate the potential risks, and establish a mitigation plan. In November 2020, the National Center for Biotechnology Information published our recommendations, “Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa),” written by Alira Health’s Antonella Bacchieri, Senior Consultant Statistician, and Paolo Morelli, Executive Vice President, Biometrics, in collaboration with Andrea Rossi, Consultant in Medical Writing, Communications and Scientific Affairs. 

The RiMiCOPa document, based on EMA and FDA guidelines, provides advice on evaluating how the different aspects of clinical trials should be handled to mitigate the impact of the COVID-19 pandemic on data management, statistics, and medical writing activities, maintaining the required quality standards.

Related news

Events May 27, 2022
PSI 2022 Conference
We are pleased to announce that this year we will be joining PSI 2022 Conference, the principal annual event for statisticians in the pharmaceutical industry, as sponsors, exhibitors, and delegates.
Biometrics
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Publications March 22, 2022
Biometrics: Industry State of Affairs
We spoke with Katell Bernois, Director of Statistical Consulting at Alira Health, to understand the key trends that are changing the biometrics industry.
Biometrics
Publications March 11, 2022
Addressing Common CDISC Compliance Findings for Regulatory Submission
Learn from the team of industry CDISC experts how to explain common SDTM/ADAM issues to regulatory reviewers.
Biometrics
Publications March 8, 2022
Case Study: Effective Early Phase Oncology Study Design
Discover more about how to use Bayesian Optimal Interval Design to effectively design an Early Phase Oncology study.
Biometrics
Publications March 8, 2022
White Paper: The Sequential Parallel Comparison Design for Reducing Placebo Response
In this white paper, we will explore a two-stage adaptive design called the “Sequential Parallel Comparison Design” (SPCD) for enrichment of placebo non-responders.
Biometrics
Events February 17, 2022
ACDM 2022
Join us at ACDM March 13-15 in Edinburgh, Scotland. Set up a meeting and speaking about how Alira Health can help you to accelerate innovation and deliver tomorrow’s standard of care.
Biometrics
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.